Angiosarcoma Clinical Trial
— ANGIHEOfficial title:
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
The purpose of this study is to test the feasibility of identifying incident cases of angiosarcoma of the liver from the network NetSarc.
Status | Active, not recruiting |
Enrollment | 9 |
Est. completion date | January 2017 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Any patient with angiosarcoma of the liver (angiosarcoma immediately multifocal allowed) diagnosed by histology from the start of the study - The patient's written Consent No exclusion criteria |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
France | Institut Bergonié | Bordeaux | |
France | Centre Jean Perrin | Clermont-ferrand | |
France | Centre Georges François | Dijon | |
France | Centre Oscar Lambret | Lille | |
France | Centre Léon Bérard | Lyon | |
France | Hôpital de la TIMONE | Marseille | |
France | CRLCC Montpellier | Montpellier | |
France | Hopital Tenon | Paris | |
France | Institut de Cancérologie Lucien | St PRIEST EN JAREZ | |
France | CHU Strasbourg | Strasbourg | |
France | Institut Claudius Regaud | Toulouse | |
France | Chu / Hopital Trousseau | Tours |
Lead Sponsor | Collaborator |
---|---|
Centre Oscar Lambret | Institut de Veille Sanitaire |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of identifying incident cases of angiosarcoma liver from the network NetSarc | Feasibility of identifying incident cases of angiosarcoma of the liver (ASF) from the network NetSarc: number of sheets indicated and returned to the Promoter. 30 cases are expected, the cumulative number of incident cases will be measured over a period of 36 months | At month 36 | No |
Secondary | Prospective surveillance in France | At month 36 | No | |
Secondary | Description of occupational risk factors and environmental | Data will be collected using a questionnaire with: Exhaustive search of all occupational and environmental exposures as known or suspected risk factors for ASF Reconstruction of residential history and haunts each case by means of a collection of successive addresses |
At month 36 | No |
Secondary | Identification of biomarkers associated with human exposure Environmental old and new to vinyl chloride monomer | Research suggestive of carcinogenesis related to CVM (identified in animal models and cohorts of workers exposed) biomarkers will be made by biological testing (blood and urine) adducts éthénobases kind resulting from the reaction of metabolites with CVM DNA and specific gene mutations k-ras and p53. Exposure to arsenic via the determination of Arsenic urinaire.sera sought. The p53 and K-ras genes are also sequences from initial diagnostic biopsies. |
At 36 month | No |
Secondary | Assessment of the amount of vinyl chloride monomèredans successive addresses or nearby for cases without occupational exposure identified | Data will be collected using a questionnaire with: - Assessment of the amount of vinyl chloride monomer (VCM) in successive addresses or nearby for cases without occupational exposure identified |
At month 36 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT01303497 -
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
|
Phase 2 | |
Recruiting |
NCT02625389 -
Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
|
Phase 4 | |
Completed |
NCT04293289 -
Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma
|
N/A | |
Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 | |
Not yet recruiting |
NCT02732678 -
Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
Recruiting |
NCT06375941 -
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
|
||
Recruiting |
NCT05799612 -
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
|
Phase 1 | |
Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
Recruiting |
NCT01042379 -
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
|
Phase 2 | |
Terminated |
NCT02212015 -
Evaluation of Votrient in Angiosarcoma
|
Phase 2 | |
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03331250 -
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
|
Phase 2 | |
Completed |
NCT02584309 -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06277154 -
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Withdrawn |
NCT04607200 -
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
|
Phase 2 | |
Completed |
NCT04518124 -
Propranolol in Angiosarcoma
|
Phase 2 | |
Recruiting |
NCT05961761 -
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
|
Phase 2 | |
Completed |
NCT00887809 -
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
|
Phase 2 |